HCTI vs. CMMB, PYPD, XWEL, BNOX, CYCN, ABVC, VAPO, HSCS, AQB, and PRPO
Should you be buying Healthcare Triangle stock or one of its competitors? The main competitors of Healthcare Triangle include Chemomab Therapeutics (CMMB), PolyPid (PYPD), XWELL (XWEL), Bionomics (BNOX), Cyclerion Therapeutics (CYCN), ABVC BioPharma (ABVC), Vapotherm (VAPO), Heart Test Laboratories (HSCS), AquaBounty Technologies (AQB), and Precipio (PRPO). These companies are all part of the "medical" sector.
Healthcare Triangle (NASDAQ:HCTI) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.
In the previous week, Chemomab Therapeutics had 1 more articles in the media than Healthcare Triangle. MarketBeat recorded 3 mentions for Chemomab Therapeutics and 2 mentions for Healthcare Triangle. Chemomab Therapeutics' average media sentiment score of 0.96 beat Healthcare Triangle's score of 0.44 indicating that Chemomab Therapeutics is being referred to more favorably in the news media.
Healthcare Triangle has higher revenue and earnings than Chemomab Therapeutics. Healthcare Triangle is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.
0.3% of Healthcare Triangle shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 2.5% of Healthcare Triangle shares are held by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Chemomab Therapeutics has a net margin of 0.00% compared to Healthcare Triangle's net margin of -37.16%. Chemomab Therapeutics' return on equity of -114.00% beat Healthcare Triangle's return on equity.
Healthcare Triangle has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.
Chemomab Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 809.09%. Given Chemomab Therapeutics' higher probable upside, analysts clearly believe Chemomab Therapeutics is more favorable than Healthcare Triangle.
Chemomab Therapeutics received 13 more outperform votes than Healthcare Triangle when rated by MarketBeat users. However, 100.00% of users gave Healthcare Triangle an outperform vote while only 58.33% of users gave Chemomab Therapeutics an outperform vote.
Summary
Chemomab Therapeutics beats Healthcare Triangle on 11 of the 16 factors compared between the two stocks.
Get Healthcare Triangle News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Healthcare Triangle Competitors List
Related Companies and Tools